Document type
OtherVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/186324
Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
A hallmark of cancer is cell death evasion, underlying suboptimal responses to chemotherapy, targeted agents, and immunotherapies. The approval of the anti apoptotic BCL2 antagonist venetoclax has fi nally validated the potential of targeting apoptotic pathways in patients with cancer. Nevertheless, pharmacologic modulators of cell death have shown markedly varied responses in preclinical and clinical studies. Here, we review emerging concepts in the use of this class of therapies. Building on these observations, we propose that treatment-induced changes in apoptotic dependency, rather than pretreatment dependencies, will need to be recognized and targeted to realize the precise deployment of these new pharmacologic agents. Signifi cance: Targeting antiapoptotic family members has proven effi cacious and tolerable in some cancers, but responses are infrequent, particularly for patients with solid tumors. Biomarkers to aid patient selection have been lacking. Precision functional approaches that overcome adaptive resistance to these compounds could drive durable responses to chemotherapy, targeted therapy, and immunotherapies.
Subject
Subject (English)
Citation
Citation
MONTERO BORONAT, Juan José and HAQ, Rizwan. Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics. Cancer Discovery. 2022. Vol. 12, num. 5, pags. 1217-1232. ISSN 2159-8290. [consulted: 9 of August of 2026]. Available at: https://hdl.handle.net/2445/186324